Pfizer reported a year-on-year increase in net profit for the quarter ended June 30, 2026 (Q1FY27), rising 6.6% to ₹204.47 crore from ₹191.75 crore in the corresponding period last year. The pharmaceutical company’s revenue from operations grew 8.3% to ₹653.17 crore, supported by an expansion in EBITDA margin to 37.9% from 34.83%. The results reflect improved operational leverage and cost management during the quarter.

The Board of Directors approved the unaudited financial results at a meeting held on July 28, 2026. The figures were reviewed by the Audit Committee and subsequently limited-reviewed by the statutory auditors, B S R & Co. LLP, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company operates in a single segment, Pharmaceuticals, and has no subsidiaries or joint ventures as of June 30, 2026.

Revenue and Profitability Performance

Pfizer’s revenue from operations stood at ₹653.17 crore in Q1FY27, compared to ₹603.05 crore in Q1FY26. Other income declined to ₹44.84 crore from ₹67.17 crore in the prior year period, resulting in total income of ₹698.01 crore against ₹670.22 crore previously.

EBITDA for the quarter was ₹246.15 crore (derived from profit before tax and exceptional items plus depreciation and finance costs), up from ₹210.14 crore in Q1FY26. The EBITDA margin expanded significantly to 37.9% from 34.83%, indicating stronger operating efficiency despite higher material costs.

Net Profit and Taxation

Net profit for the quarter increased to ₹204.47 crore from ₹191.75 crore in Q1FY26. Profit before tax rose to ₹276.68 crore from ₹259.53 crore. Tax expense for the quarter was ₹72.21 crore (current tax ₹70.93 crore and deferred tax ₹1.28 crore), compared to ₹67.78 crore in the previous year.

Earnings per share (basic and diluted) grew 6.6% to ₹44.69 per share from ₹41.91 per share in Q1FY26. The company’s paid-up equity share capital remained unchanged at ₹45.75 crore.

What the Numbers Show

The divergence between revenue growth (8.3%) and net profit growth (6.6%) suggests that while top-line momentum is strong, cost pressures partially offset margin gains. However, the significant expansion in EBITDA margin (+307 basis points) indicates that operational efficiencies—likely in employee benefits and other expenses—are driving profitability more than volume growth alone. The decline in other income (from ₹67.17 crore to ₹44.84 crore) highlights that core operational performance is now the primary driver of earnings, reducing reliance on non-operating income streams.

Pfizer Limited has disclosed the resignation of Amit Agarwal, who serves as Executive Director – Finance & Chief Financial Officer. The departure is effective October 8, 2026, at close of business. Agarwal stated he is leaving to pursue a professional opportunity outside the company.

The resignation was communicated to the Bombay Stock Exchange and the National Stock Exchange of India Ltd on July 27, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also complies with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Upon his exit, Agarwal will cease to hold his position on the Board of Directors. He will also step down from all Board committees where he currently serves as a member. These include the Corporate Social Responsibility Committee, the Risk Management Committee, and the Board Administrative & Share Transfer Committee.

Resignation Details

The following table outlines the key details of the leadership change as per the filing:

In his resignation letter addressed to the Board of Directors, Agarwal expressed gratitude for the trust and support received during his tenure. Prajeet Nair, Director – Corporate Services & Company Secretary, signed the intimation letter sent to the stock exchanges.